ClinicalTrials.gg
Not yet recruitingNCT07737964ACHIEVEUpdated Aug 17, 2026

ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

A Phase 3 interventional study of Acetazolamide and Furosemide in Heart Failure, sponsored by University Hospital, Montpellier. Not yet recruiting at 25 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by University Hospital, Montpellier · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.

Planned enrollment
4th of 14
366 · median 66
Started
2026
with 2 others
Phase 3
3 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies testing acetazolamide in Heart Failure, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 13th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About acetazolamide

Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing acetazolamide in Heart Failure, or all of them as a file.
02

Study summary

Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations.

ACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring.

The primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • heart failure
  • congestion
  • ambulatory treatment
  • remote telemonitoring
  • diuretics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Known HF with impaired, midly-reduced or preserved
  • Under guideline directed medical therapy for HF according to ESC Heart Failure Guidelines applicable at inclusion
  • Previously followed (or included at hospital discharge) by remote monitoring allowing daily weight by connected scale (i.e. Careline®, Optified-self®, NewCard®, Implicity®)
  • Under furosemide diuretic treatment ≥ 20mg/day for at least 30 days prior to inclusion
  • Current unplanned hospitalization or unplanned/emergent consultation for acute/decompensation HF

Exclusion criteria

Exclusion Criteria:

  • Subject unable to express their consent and sign form
  • Subject not covered by public health insurance
  • Refusal to participate (absence of informed consent).
  • Subject under guardianship, legal protection, or deprived of liberty.
  • Pregnant or breastfeeding women.
  • Subject under law protection and prisoners
  • Women of child bearing potential, unless they are using an effective method of (i.e. oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner)
  • Subject unable to comprehend or adhere to the protocol and follow-up
  • Concurrent participation in another interventional study.
  • Chronic ventricular assist device or heart transplant patients.
  • Acute heart failure from recent acute coronary syndrome (\< 1 month).
  • Severe chronic renal failure or dialysis ( \< 20 ml/min).
  • History of renal colic, hyperchloremic acidosis and wheat allergy (other than coeliac disease)
  • Known severe hepatic insufficiency defined by a \< 50% or a score C and/or a known (clinial or biological) supplemented adrenal insufficiency
  • Intolerance to sulphonamides
  • to the active substance (Acetazolamide) or to any of the (Calcium carbonate, wheat starch, gelatine, magnesium stearate)
  • Concomitant use of carbamazepine or quinidinics (hydroquinidine, quinidine)
  • Low cardiac output syndrome/cardiogenic shock.
  • Current use of acetazolamide or any other carbonic anhydrase inhibitor, including but not limited to topical ophthalmic formulations (e.g., brinzolamide, dorzolamide, methazolamide)
  • Concomitant use of lithium, valproic acid and valpromide
  • Current use of high-dose aspirin (>300 mg/day).

Non-randomization criteria (Criteria should be controlled before patients' randomization) :

  • False alarm
  • Time between alarm and randomization > 48h
  • Subject who declines his participation
  • Loss of study treatments or unable to take it at D0
  • Hemodynamic instability justifying an urgent hospitalization
  • If applicable, positive urine pregnancy test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    Experimental group - Acetazolamide

    Ambulatory patients with decompensated heart failure receiving standard treatment with loop diuretics (furosemide) plus oral acetazolamide for up to 5 days. Treatment effectiveness and safety are assessed daily using remote telemonitoring data.

    Drug: Acetazolamide · Drug: Furosemide

  • Active comparator
    Control group - Standard treatment

    Ambulatory patients with decompensated heart failure receiving standard treatment with loop diuretics (furosemide) alone for up to 5 days. Treatment effectiveness and safety are assessed daily using remote telemonitoring data.

    Drug: Furosemide

Interventions

  • Oral acetazolamide initiated at 500 mg (2 tablets) on Day 0. The dose may be adjusted every 48 hours according to the participant's clinical status until Day 5, if necessary.

  • Standard treatment with loop diuretics (furosemide) administered for up to 5 days according to standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with weight loss >2 kg at Day

    Percentage of participants who achieve a body weight loss greater than 2 kg between baseline (Day 0) and Day 5, measured using a connected scale through the remote telemonitoring system. Comparison between the experimental and control groups.

    Time frame: Day 5

Secondary outcomes

  1. Efficacy : Percentage of weight variation

    Percentage change in body weight between Day 0 and Day 5 measured using a connected scale through the remote telemonitoring system.

    Time frame: Day 0 to Day 5

  2. Efficacy : Diuretic effectiveness

    Diuretic effectiveness assessed by urinary sodium excretion (natriuresis) corrected for loop diuretic exposure, expressed according to furosemide-equivalent dose administered up to Day 5.

    Time frame: Day 5

  3. Efficacy : Change in NT-proBNP concentration

    Change in plasma NT-proBNP concentration measured from blood samples between baseline and Day 5.

    Time frame: Day 0 to Day 5

  4. Efficacy : Change in health-related quality of life (EQ-5D-5L)

    Change in EQ-5D-5L score between baseline (Day 0) and Day 5. The EQ-5D-5L is a validated generic quality-of-life questionnaire assessing five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).Each question has 5 levels of answers: No problem, slight problems, moderate problems, severe problems and unable to/ extreme problems. It also includes a visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Day 0 to Day 5

  5. Efficacy : Change in dyspnea Visual Analogue Scale (VAS) score

    Change in dyspnea severity assessed using a Visual Analogue Scale (VAS) between baseline (Day 0) and Day 5. The VAS ranges from 0 (no shortness of breath) to 10 (worst shortness of breath imaginable).

    Time frame: Day 0 to Day 5

  6. Efficacy : Rate of unplanned consultation or hospitalization for heart failure

    Percentage of participants requiring an unplanned medical consultation, emergency department visit, or hospitalization for heart failure

    Time frame: Day 90

  7. Efficacy : All-cause mortality

    Percentage of participants who die from any cause.

    Time frame: Day 90

  8. Efficacy : All-cause mortality and Heart failure-related mortality

    Percentage of participants who die any cause or from heart failure during follow-up.

    Time frame: Day 90

  9. Efficacy : Change in clinical congestion parameters

    Evolution of clinical congestion including body weight, dyspnea VAS score, blood pressure, heart rate, and signs of right- and left-sided heart failure collected during follow-up visits.

    Time frame: At Day 15

  10. Efficacy : Change in NT-proBNP concentration

    Change in plasma NT-proBNP concentration measured on blood samples collected after the acute treatment period.

    Time frame: At Day 15

  11. Safety : Change in serum sodium concentration

    Assessment of the change in serum sodium concentration between baseline Day 0 and Day 5 to evaluate electrolyte disturbances associated with treatment.

    Time frame: Day 0 to Day 5

  12. Safety : Percentage of participants with serum sodium <125 mmol/L

    Percentage of participants presenting severe hyponatremia, defined as a serum sodium concentration below 125 mmol/L, on Day 5.

    Time frame: Day 5

  13. Safety: Incidence of acute kidney injury (KDIGO stage ≥2)

    Percentage of participants developing acute kidney injury defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or higher between D0 and D5.

    Time frame: Day 0 to Day 5

  14. Safety : Change in serum potassium concentration

    Assessment of the change in serum potassium concentration between baseline Day 0 and Day 5 to evaluate treatment related electrolyte abnormalities.

    Time frame: Day 0 to Day 5

  15. Safety: Percentage of participants with serum potassium <2.5 mmol/L

    Percentage of participants presenting severe hypokalemia, defined as a serum potassium concentration below 2.5 mmol/L, on Day 5.

    Time frame: Day 5

  16. Safety: Change in serum bicarbonate concentration from Day 0 to Day 5

    Assessment of the change in serum bicarbonate concentration between baseline Day 0 and Day 5 to evaluate metabolic changes associated with treatment.

    Time frame: Day 0 to Day 5

  17. Percentage of participants with serum bicarbonate <20 mmol/L

    Percentage of participants presenting serum bicarbonate concentrations below 20 mmol/L on Day 5.

    Time frame: Day 5

  18. Safety: Change in systolic blood pressure

    Assessment of the change in systolic blood pressure between baseline Day 0 and Day 5 during treatment.

    Time frame: Day 0 to Day 5

  19. Safety: Percentage of participants with systolic blood pressure <90 mmHg

    Percentage of participants presenting systolic blood pressure below 90 mmHg during treatment.

    Time frame: Day 0 to day 5

  20. Safety: Incidence of low cardiac output or cardiogenic shock

    Percentage of participants developing low cardiac output syndrome or cardiogenic shock between D0 and D5.

    Time frame: Day 0 to Day 5

  21. Safety: Hospitalization due to treatment failure or poor treatment tolerance

    Percentage of participants requiring hospitalization because of treatment failure or poor treatment tolerance.

    Time frame: Day 5 and Day 15

  22. Medicoeconomic: Hospital medical costs

    Difference in direct hospital medical costs related to unplanned consultations, emergency department visits, or hospitalizations between the experimental and control groups. Costs will be assessed using actual reimbursement tariffs and hospital revenues.

    Time frame: Day 90

07

Study locations

25 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 27 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartEst.
Oct 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07737964
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Aug 17, 2026

Study contacts

François ROUBILLE, MD
Contact
f-roubille@chu-montpellier.fr
04 67 33 31 82
Clément Delmas, MD
Contact
delmas.clement@chu-toulouse.fr
François ROUBILLE, MD
study director · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetazolamide

Start the discussion